Published in Cancer Weekly, April 4th, 2000
"Recombinant IL-2 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every eight hours for up to 14 consecutive doses over five days as clinically tolerated with maximal support" in the original study, last updated in December 1998, explained R.I. Fisher and colleagues at Loyola University ("Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma," Cancer Journal from Scientific American, 2000;6(Suppl. 1):S55-S57).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.